Use of bissulfonamides for producing medicines for the...

Details Use of bissulfonamides for producing medicines for the... Use of bissulfonamides for producing medicines for the...

2000-08-31

2003-10-14

Padmanabhan, Sreeni (Department: 1617)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Nitrogen containing other than solely as a nitrogen in an...

C514S603000, C514S601000, C514S252110, C514S252120, C514S331000, C514S326000

Reexamination Certificate

active

06632838

ABSTRACT:

The invention relates to the use of bissulfonamides and their physiologically tolerated salts and physiologically functional derivatives for producing medicines for the prevention and treatment of hyperlipidemia and arteriosclerotic disorders.
U.S. Pat. No. 3,876,632 describes bissulfonamides as antihypertensives.
The invention was based on the object of providing compounds which display a therapeutically utilizable hypolipidemic effect.
The invention therefore relates to the use of compounds of formula I
in which:
X, R1, and R2 are, independently of one another, NR6R7, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, or tetrahydropyridinyl, in which each ring is optionally substituted independently of one another by phenyl, (C
1
-C
6
)-alkyl-phenyl, (C
1
-C
6
)-alkyl, (C
1
-C
6
)-alkyl-OH, O-phenyl, S-phenyl, (CO)—(C
1
-C
6
)-alkyl, or (CO)-phenyl, where the phenyl substituent is unsubstituted or mono- or disubstituted independently of one another by F, Cl, Br, OH, CF
3
, CN, OCF
3
, O—(C
1
-C
6
)-alkyl, S—(C
1
-C
6
)-alkyl, SO—(C
1
-C
6
)-alkyl, SO
2
—(C
1
-C
6
)-alkyl, (C
1
-C
6
)-alkyl, (C
3
-C
6
)-cycloalkyl, COOH, COO(C
1
-C
6
)alkyl, COO(C
3
-C
6
)cycloalkyl, CONH
2
, CONH(C
1
-C
6
)alkyl, CON[(C
1
-C
6
)alkyl]
2
, CONH(C
3
-C
6
)cycloalkyl, NH
2
, NH—CO—(C
1
-C
6
)-alkyl, or NH—CO-phenyl;
R6 and R7 are, independently of one another, H, (C
1
-C
6
)-alkyl, (C
1
-C
6
)-alkyl-O—(C
1
-C
6
)-alkyl, O—(C
1
-C
6
)-alkyl, (C
3
-C
6
)-cycloalkyl, CO—(C
1
-C
6
)-alkyl, (C
1
-C
6
)-alkyl-NH—C(O)—(C
1
-C
6
)-alkyl, (C
1
-C
6
)-alkyl-NH—(C
1
-C
6
)-alkyl, (C
1
-C
6
)-alkyl-N—[(C
1
-C
6
)-alkyl]
2
, (C
1
-C
6
)-alkyl-O-phenyl, CHO, CO-phenyl, or (CH
2
)
n
—Ar, where n is optionally the integer 0, 1, 2, 3, 4, 5, or 6, and Ar is chosen from phenyl, biphenylyl, 1- or 2-naphthyl, 1- or 2-tetrahydrofuranyl, 2-, 3-, or 4-pyridyl, 2- or 3-thienyl, 2- or 3-furyl, 2-, 4-, or 5-thiazolyl, 2-, 4-, or 5-oxazolyl, 1-pyrazolyl, 3-, 4-, or 5-isoxazolyl, (C
3
-C
6
)-cycloalkyl, piperidinyl, pyrrolidinyl, 2- or 3-pyrrolyl, 2- or 3-pyridazinyl, 2-, 4-, or 5-pyrimidinyl, 2-pyrazinyl, 2-(1,3,5-triazinyl), 2-, 3-, or 4-morpholinyl, 2- or 5-benzimidazolyl, 2-benzothiazolyl, 1,2,4-triazol-3-yl, 1,2,4-triazol-5-yl, tetrazol-5-yl, indol-3-yl, indol-5-yl, or N-methyl-imidazol-2-, -4-, or -5-yl, and Ar is optionally mono- or disubstituted independently of one another by F, Cl, Br, OH, CF
3
, NO
2
, CN, OCF
3
, O—CH
2
—O, O—(C
1
-C
6
)-alkyl, S—(C
1
-C
6
)-alkyl, SO—(C
1
-C
6
)-alkyl, SO
2
—(C
1
-C
6
)-alkyl, (C
1
-C
6
)-alkyl, (C
3
-C
6
)-cycloalkyl, COOH, COO(C
1
-C
6
)alkyl, COO(C
3
-C
6
)cycloalkyl, CONH
2
, CONH(C
1
-C
6
)alkyl, CON[(C
1
-C
6
)alkyl]
2
, CONH(C
3
-C
6
)cycloalkyl, NH
2
, NH—CO—(C
1
-C
6
)-alkyl, NH—CO-phenyl, pyrrolidin-1-yl, morpholin-1-yl, piperidin-1-yl, piperazin-1-yl, 4-methyl-piperazin-1-yl, (CH
2
)
n
-phenyl, O—(CH
2
)
n
-phenyl, S—(CH
2
)
n
-phenyl, or SO
2
—(CH
2
)
n
-phenyl, where n is the integer 0, 1, 2, or 3;
or a physiologically tolerated salt or a physiologically functional derivative thereof for producing a medicine for the prevention and treatment of hyperlipidemia.
It is preferred to use compounds of formula I in which one or more radical(s) has or have the following meaning:
R1 is NR6R7, pyrrolidinyl, piperidinyl, piperazinyl, or tetrahydropyridinyl, in which each ring is optionally substituted independently of one another by phenyl, (C
1
-C
6
)-alkyl-phenyl, (C
1
-C
6
)-alkyl, (C
1
-C
6
)-alkyl-OH, O-phenyl, S-phenyl, (CO)—(C
1
-C
6
)-alkyl, or (CO)-phenyl, where the phenyl substituent is unsubstituted or mono- or disubstituted independently of one another by F, Cl, Br, CF
3
, CN, OCF
3
, O—(C
1
-C
6
)-alkyl, S—(C
1
-C
6
)-alkyl, (C
1
-C
6
)-alkyl, (C
3
-C
6
)-cycloalkyl, COOH, COO(C
1
-C
6
)-alkyl, COO(C
3
-C
6
)cycloalkyl, CONH
2
, CONH(C
1
-C
6
)alkyl, CON[(C
1
-C
6
)alkyl]
2
, NH
2
, NH—CO—(C
1
-C
6
)-alkyl, or NH—CO-phenyl;
R6 and R7 are, independently of one another, H, (C
1
-C
6
)-alkyl, (C
1
-C
6
)-alkyl-O—(C
1
-C
6
)-alkyl, (C
3
-C
6
)-cycloalkyl, CO—(C
1
-C
6
)-alkyl, (C
1
-C
6
)-alkyl-NH—C(O)—(C
1
-C
6
)-alkyl, (C
1
-C
6
)-alkyl-NH—(C
1
-C
6
)-alkyl, (C
1
-C
6
)-alkyl-N—[(C
1
-C
6
)-alkyl]
2
, or (CH
2
)
n
—Ar, where n is optionally the integer 0,1, 2, 3, 4, 5, or 6, and Ar is chosen from phenyl, biphenylyl, 1- or 2-naphthyl, 2-, 3-, or 4-pyridyl, 2- or 3-thienyl, 2-, 4-, or 5-thiazolyl, 2-, 4-, or 5-oxazolyl, 3- or 5-isoxazolyl, (C
3
-C
6
)-cycloalkyl, piperidinyl, pyrrolidinyl, 2-, 4-, or 5-pyrimidinyl, 2-, 3-, or 4-morpholinyl, 2- or 5-benzimidazolyl, 2-benzothiazolyl, indol-3-yl, or indol-5-yl, and Ar is optionally mono- or disubstituted independently of one another by F. Cl, Br, OH, CF
3
, NO
2
, CN, OCF
3
, O—(C
1
-C
6
)-alkyl, S—(C
1
-C
6
)-alkyl, SO—(C
1
-C
6
)-alkyl, SO
2
—(C
1
-C
6
)-alkyl, (C
1
-C
6
)-alkyl, (C
3
-C
6
)-cycloalkyl, COOH, COO(C
1
-C
6
)alkyl, COO(C
3
-C
6
)cycloalkyl, CONH
2
, CONH(C
1
-C
6
)alkyl, NH
2
, NH—CO-phenyl, (CH
2
)
n
-phenyl, O—(CH
2
)
n
-phenyl, or S—(CH
2
)
n
-phenyl, where n is the integer 0, 1, 2, or 3;
R2 is NR8R9 or piperazinyl, in which piperazinyl is optionally substituted independently of one another by (C
1
-C
6
)-alkyl-phenyl, (C
1
-C
6
)-alkyl, (C
1
-C
6
)-alkyl-OH, O-phenyl, S-phenyl, (CO)—(C
1
-C
6
)-alkyl, or (CO)-phenyl;
R8 and R9 are, independently of one another, H, (C
1
-C
6
)-alkyl, (C
3
-C
6
)-cycloalkyl, CO—(C
1
-C
6
)-alkyl, (C
1
-C
6
)-alkyl-NH—(C
1
-C
6
)-alkyl, (C
1
-C
6
)-alkyl-N—[(C
1
-C
6
)-alkyl]
2
, or (CH
2
)
n
—Ar, where n is the integer 0, 1, 2, 3, 4, 5, or 6, and Ar is chosen from phenyl, 2-, 3-, or 4-pyridyl, piperidinyl, pyrrolidinyl, or morpholinyl;
X is NR10R11, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl, in which each ring is optionally substituted independently of one another by phenyl, (C
1
-C
6
)alkyl-phenyl, (C
1
-C
6
)-alkyl, (C
1
-C
6
)-alkyl-OH, O-phenyl, S-phenyl, (CO)—(C
1
-C
6
)-alkyl, or (CO)-phenyl, where the phenyl substituent is unsubstituted or mono- or disubstituted independently of one another by F, Cl, Br, CF
3
, CN, OCF
3
, O—(C
1
-C
6
)-alkyl, (C
1
-C
6
)-alkyl, (C
3
-C
6
)-cycloalkyl, COOH, COO(C
1
-C
6
)-alkyl, COO(C
3
-C
6
)cycloalkyl, CONH
2
, CONH(C
1
-C
6
)alkyl, CON[(C
1
-C
6
)alkyl]
2
, NH
2
, NH—CO—(C
1
-C
6
)-alkyl, or NH—CO-phenyl;
R10 and R11 are, independently of one another, H, (C
1
-C
6
)-alkyl, (C
1
-C
6
)-alkyl-O—(C
1
-C
6
)-alkyl, (C
3
-C
6
)-cycloalkyl, CO—(C
1
-C
6
)-alkyl, (C
1
-C
6
)-alkyl-NH—(C
1
-C
6
)-alkyl, (C
1
-C
6
)-alkyl-N—[(C
1
-C
6
)-alkyl]
2
, CO-phenyl, or (CH
2
)
n
—Ar, where n is the integer 0, 1, 2, 3, 4, 5, or 6, and Ar is chosen from phenyl, biphenylyl, 1- or 2-naphthyl, 1- or 2-tetrahydrofuranyl, 2-, 3-, or 4-pyridyl, 2- or 3-thienyl, 2- or 3-furyl, 2-, 4-, or 5-thiazolyl, 2-, 4-, or 5-oxazolyl, 3- or 5-isoxazolyl, piperidinyl, pyrrolidinyl, 2-, 4-, or 5-pyrimidinyl, 2-, 3-, or 4-morpholinyl, or 2-benzothiazolyl, and Ar is optionally mono- or disubstituted independently of one another by F, Cl, Br, OH, CF
3
, NO
2
, CN, OCF
3
, O—(C
1
-C
6
)-alkyl, S—(C
1
-C
6
)-alkyl, SO—(C
1
-C
6
)-alkyl, SO
2
—(C
1
-C
6
)-alkyl, (C
1
-C
6
)-alkyl, (C
3
-C
6
)-cycloalkyl, CONH
2
, CONH(C
1
-C
6
)alkyl, CON[(C
1
-C
6
)alkyl]
2
, NH—CO—(C
1
-C
6
)-alkyl, NH—CO-phenyl, or (CH
2
)
n
-phenyl where n is the integer 0, 1, 2, or 3;
or a physiologically tolerated salt or a physiologically functional derivative thereof for producing a medicine for the prevention and treatment of hyperlipidemia.
It is particularly preferred to use compounds of formula I in which one or more radical(s) has or have the following meaning:
R1 is NR6R7, piperidinyl, piperazinyl, or tetrahydropyridinyl, in which each ring is optionally substituted independently of one another by phenyl or (C
1
-C
6
)-alkyl-phenyl;
R6 and R7 are, independently of one another, H, (C
1
-C
6
)-alkyl, (C
1
-C
6
)-alkyl-O—(C
1
-C
6
)-alkyl, (C
3
-C
6
)-cycloalkyl, (C
1
-C
6
)-alkyl-NH—C(O)—(C
1
-C
6
)-alkyl, (C
1
-C
6
)-alkyl-NH—(C
1
-C
6
)-alkyl, (C
1
-C
6
)-alkyl-N—[(C
1
-C
6
)-al

Affiliated with

Also associated with

Rating

Use of bissulfonamides for producing medicines for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of bissulfonamides for producing medicines for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of bissulfonamides for producing medicines for the... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3174084